Tertiary drug information sources for treatment and prevention of COVID-19
Keywords:Drug Information, Tertiary Databases, COVID-19, Evaluation Studies
Objective: To evaluate tertiary drug information databases in terms of scope, consistency of content, and completeness of COVID-19 drug information.
Methods: Five electronic drug information databases: Clinical Pharmacology, Lexi-Drugs, AHFS DI (American Hospital Formulary Service Drug Information), eFacts and Comparisons, and Micromedex In-Depth Answers, were evaluated in this cross-sectional evaluation study, with data gathered from October 2021 through February 2022. Two study investigators independently extracted data (parallel extraction) from each resource. Descriptive statistics were primarily used to evaluate scope (i.e., whether the resource addresses use of the medication for treatment or prevention of COVID-19) and completeness of content (i.e., whether full information is provided related to the use of the medication for treatment or prevention of COVID-19) based on a 10-point scale. To analyze consistency among resources for scope, the Fleiss multi-rater kappa was used. To analyze consistency among resources for type of recommendation (i.e., in favor, insufficient evidence, against), a two-way mixed effects intraclass coefficient was calculated.
Results: A total of 46 drug monographs, including 3 vaccination monographs, were evaluated. Use of the agents for treatment of COVID-19 was most frequently addressed in Lexi-Drugs (73.9%), followed by eFacts and Comparisons (71.7%), and Micromedex (54.3%). The highest overall median completeness score was held by AHFS DI followed by Micromedex, and Clinical Pharmacology. There was moderate consistency in terms of scope (kappa 0.490, 95% CI 0.399-0.581, p<0.001) and recommendations (intraclass correlation coefficient 0.518, 95% CI 0.385-0.651, p<0.001).
Coronavirus Resource Center. Mortality Analyses [Internet]. Johns Hopkins University & Medicine; 2022 [cited 25 Oct 2022]. https://coronavirus.jhu.edu/data/mortality.
Park JJH, Mogg R, Smith GE, Nakimuli-Mpungu E, Jehan F, Rayner CR, Condo J, Decloedt EH, Nachega JB, Reis G, Mills EJ. How COVID-19 has fundamentally changed clinical research in global health. Lancet Glob Health. 2021 May;9(5):e711-20. DOI: http://dx.doi.org/10.1016/S2214-109X(20)30542-8.
Elkin ME, Zhu X. Understanding and predicting COVID-19 clinical trial completion vs. cessation. PLoS One. 2021 Jul;16(7):e0253789. DOI: http://dx.doi.org/10.1371/journal.pone.0253789.
U.S. Food & Drug Administration. Coronavirus Treatment Acceleration Program (CTAP). The Administration; 2022 [cited 25 Oct 2022]. https://www.fda.gov/drugs/coronavirus-covid-19-drugs/coronavirus-treatment-acceleration-program-ctap.
Shi J, Xiao Y, Zhang Y, Geng D, Cong D, Shi KX, Knapp RJ. Challenges of drug development during the COVID-10 pandemic: key considerations for clinical trial designs. Br J Clin Pharmacol. 2021 May;87(5):2170-85. DOI: http://dx.doi.org/10.1111/bcp.14629.
Clout AE, Pasqua OD, Hanna MG, Orlu M, Pitceathly RDS. Drug repurposing in neurological diseases: an integrated approach to reduce trial and error. J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1270-5. DOI: http://dx.doi.org/10.1136/jnnp-2019-320879.
Cornish L, Jerving S, Ravelo JL. Data around COVID-19 is a mess and here’s why that matters [Internet]. Devex; 2020 [cited 25 Oct 2022]. < https://www.devex.com/news/data-around-covid-19-is-a-mess-and-here-s-why-that-matters-97077>.
Clinical Pharmacology powered by ClinicalKey [Internet]. Elsevier; 2022 [cited 14 Oct 2022]. https://www.clinicalkey.com/pharmacology.
Lexicomp®. Lexi-Drugs [Internet]. UpToDate, Inc.; 2022 [cited 14 Oct 2022]. http://online.lexi.com/lco/action/home.
Lexicomp®. AHFS Drug Information [Internet]. American Society of Health System Pharmacists; 2022 [cited 14 Oct 2022]. http://online.lexi.com/lco/action/home.
Lexicomp®. Facts and Comparisons [Internet]. UptoDate, Inc.; 2022 [cited 14 Oct 2022]. http://online.lexi.com/lco/action/home.
IBM Micromedex® In-Depth Answers [Internet]. IBM Corporation; 2022 [cited 14 Oct 2022]. http://www.micromedexsolutions.com/micromedex2.
Rothgeb A, Beckett RD, Daoud N. Off-label use information in electronic drug information resources. J Med Libr Assoc. 2022. Accepted manuscript, In-Press.
Guy J, Portillo I, Beckett RD, Gill K, Mitchell K, Nissen J, Shenoy P. AACP Basic Resources for Pharmacy Education [Internet]. American Association of Colleges of Pharmacy; 2021 [cited 25 Oct 2022].
Clauson KA, Marsh WA, Polen HH, Seamon M, Ortiz BI. Clinical decision support tools: analysis of online drug information databases. BMC Med Inform Decis Mak. 2007 Mar. 7:7. DOI: http://dx.doi.org/10.1186/1472-6947-7-7.
Beckett RD, Martin JR, Stump CD, Dyer MA. Evaluation of drug information resources for interactions between therapeutic drugs and drugs of abuse. J Med Libr Assoc. 2020 Oct;108(4):584-590. http://dx.doi:10.5195/jmla.2020.969.
Beckett RD, Stump CD, Dyer MA. Evaluation of drug information resources for drug-ethanol and drug-tobacco interactions. J Med Libr Assoc. 2019 Jan;107(1):62-71. http://dx.doi:10.5195/jmla.2019.549.
National Institute for Health and Care Excellence. COVID-19 Rapid Guideline: Managing COVID-19 [Internet]. The Institute; 2021 [cited 25 Oct 2022]. https://www.nice.org.uk/guidance/ng191.
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. The Institutes; 2022 [cited 25 Oct 2022]. https://www.covid19treatmentguidelines.nih.gov/.
Surviving Sepsis Campaign. COVID-19 Guidelines [Internet]. The Campaign; 2020 [cited 25 Oct 2022]. https://www.sccm.org/SurvivingSepsisCampaign/Guidelines/COVID-19.
DiCenzo R, ed. Clinical Pharmacist’s Guide to Biostatistics and Literature Evaluation. 2nd ed. American College of Clinical Pharmacy; 2015.
Marcath LA, Xi J, Hoylman EK, Kidwell KM, Kraft SL, Hertz DL. Comparison of nine tools for screening drug-drug interactions of oral oncolytics. J Oncol Pract. 2018 Jun;14(6):e368-e374. http://dx.doi:10.1200/JOP.18.00086.
Chang JS, Pham DA, Dang MT, Lu Y, VanOsdol S, Shin J. Evaluation of popular drug information resources on clinically useful and actionable pharmacogenomic information. J Med Libr Assoc. 2016 Jan;104(1):58-61. http://dx.doi:10.3163/1536-5050.
Vaughan KT, Scolaro KL, Anksorus HN, Roederer MW. An evaluation of pharmacogenomic information provided by five common drug information resources. J Med Libr Assoc. 2014 Jan;102(1):47-51. http://dx.doi:10.3163/1536-5050.102.1.009.
Polen HH, Zapantis A, Clauson KA, Jebrock J, Paris M. Ability of online drug databases to assist in clinical decision-making with infectious disease therapies. BMC Infect Dis. 2008 Nov 6;8:153. http://dx.doi:10.1186/1471-2334-8-153.
Drwiega EN, Badowski ME, Michienzi S. Antiretroviral drug-drug interactions: A comparison of online drug interaction databases. J Clin Pharm Ther. 2022 Oct;47(10):1720-1724. http://dx.doi:10.1111/jcpt.13750.
AHFS Drug Information® and AHFS DI® Essentials [Internet]. American Society of Health System Pharmacists; 2023 [cited 4 April 2023]. https://www.ashp.org/products-and-services/database-licensing-and-integration/ahfs-drug-information-and-ahfs-di-essentials.
Micromedex [Internet]. Merative; 2023 [cited 4 April 2023]. https://www.merative.com/clinical-decision-support.
Editorial Process for Lexicomp [Internet]. Wolters Kluwer; 2023 [cited 5 April 2023]. https://www.wolterskluwer.com/en/solutions/lexicomp/about/content-editorial-process.
Clinical Pharmacology Powered by ClinicalKey® [Internet]. Elsevier; 2023 [cited 5 April 2023]. https://elsevierresources.com/clinical-pharmacology-ck/.
Copyright (c) 2023 Robert D Beckett, Yashawna Brattain, Judy Truong, Genevieve Engle
This work is licensed under a Creative Commons Attribution 4.0 International License.